BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more ...

After its sudden rise and precipitous fall during the COVID-19 pandemic, Emergent BioSolutions is taking measured steps as it ...

Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to ...

Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has ...

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS – Free Report) from a hold rating to a buy rating in a report released on Tuesday morning. EBS has been the topic of several other ...

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...

HC Wainwright reiterated their buy rating on shares of Emergent BioSolutions (NYSE:EBS – Free Report) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a ...

Emergent BioSolutions Inc. (NYSE:EBS), currently trading at $9.43 and showing a remarkable 356% return over the past year, announced today that its President and CEO, Joe C. Papa, presented at the ...

(RTTNews) - Emergent BioSolutions (EBS), a life sciences company, on Tuesday announced that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada for ...

ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Africa CDC's support for the MOSA, a pan-African randomized platform ad ...